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Summary
 
The role of two central residues (K68, E69) of the fourth hypervariable loop of the V
 
a
 
 domain
(HV4
 
a
 
) in antigen recognition by an MHC class II–restricted T cell receptor (TCR) has been
analyzed. The TCR recognizes the NH
 
2
 
-terminal peptide of myelin basic protein (Ac1-11,
acetylated at NH
 
2
 
 terminus) associated with the class II MHC molecule I-A
 
u
 
. Lysine 68 (K68)
and glutamic acid 69 (E69) of HV4
 
a
 
 have been mutated both individually and simultaneously
to alanine (K68A, E69A). The responsiveness of transfectants bearing wild-type and mutated
TCRs to Ac1-11–I-A
 
u
 
 complexes has been analyzed in the presence and absence of expression
of the coreceptor CD4. The data demonstrate that in the absence of CD4 expression, K68
plays a central role in antigen responsiveness. In contrast, the effect of mutating E69 to alanine
is less marked. CD4 coexpression can partially compensate for the loss of activity of the K68A
mutant transfectants, resulting in responses that, relative to those of the wild-type transfectants,
are highly sensitive to anti-CD4 antibody blockade. The observations support models of T cell
activation in which both the affinity of the TCR for cognate ligand and the involvement of
coreceptors determine the outcome of the T cell–antigen-presenting cell interaction.
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F
 
or the vast majority (90–95%) of T cells, the T cell re-
ceptor (TCR) is composed of a heterodimer of highly
diverse transmembrane 
 
a
 
 and 
 
b
 
 chains, whereas a minor
population bear 
 
gd
 
 TCRs. These 
 
ab
 
 or 
 
gd
 
 heterodimers
associate with the nonpolymorphic CD3 and TCR
 
z
 
 chains
to form the functional TCR–CD3 complex. The 
 
ab
 
 het-
erodimer interacts with cognate peptide–MHC (pMHC)
complexes, whereas the CD3–TCR
 
z
 
 chain complex is
involved in signal transduction. These TCR-associated
polypeptides contain tyrosine motifs (called immune recep-
tor tyrosine-based activation motifs, or ITAMs), which are
the targets of phosphorylation following TCR triggering
(1). ITAM phosphorylation leads to recruitment of SH2
domain containing proteins, such as ZAP-70 and subse-
quent signaling cascades (1), and is one of the early events
of T cell activation (2, 3).
The extracellular domains of the TCR resemble the Fab
arms of an antibody at both the sequence and structural
levels, although there are also significant differences in both
complementarity determining regions (CDRs) and overall
fold for both 
 
a
 
 and 
 
b
 
 chains (4–6). Structural modeling of
TCR–pMHC complexes led to the suggestion that the less
diverse CDRs 1 and 2 of the TCR 
 
a
 
 and 
 
b
 
 chain make
contacts with the 
 
a
 
 helices of the MHC molecule, whereas
the highly variable CDR3 loops interact directly with the
antigenic peptide (7–9). More recent X-ray crystallo-
graphic structures of mouse and human TCR 
 
ab
 
–pMHC
class I complexes (10–13) are consistent with these pro-
posed three-dimensional models insofar as CDR3 residues
overlie, but do not always make intimate contact with, an-
tigenic peptide, whereas CDR1 and CDR2 residues are
positioned to contact primarily MHC residues with more
limited peptide contacts. The X-ray structures (10–13)
demonstrate a diagonal orientation of the TCR with re-
spect to pMHC in a configuration that is most likely to be
general, at least for pMHC class I complexes. Earlier struc-
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Abbreviations used in this paper:
 
 APC, antigen-presenting cell; CD, circular
dichroism; CDR, complementarity determining region; E69, glutamic
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a
 
, the fourth hypervari-
able loop of the V
 
a
 
 domain; ITAM, immune receptor tyrosine-based ac-
tivation motif; K68, Lysine 68; K68A, mutation of K68 to alanine; MBP,
myelin basic protein; PBS, phosphate-buffered saline; pMHC, peptide–
major histocompatibility complex; TCR, T cell receptor. 
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ture-function studies of both MHC class I and class II re-
stricted TCRs led to the proposal of a similar orientation
(14–16), but whether this configuration is generally ob-
served in TCR 
 
ab
 
–pMHC class II complexes awaits the
elucidation of the corresponding X-ray structures.
Current models of T cell activation support a role for the
affinity/avidity of the TCR–pMHC as being a key param-
eter in the outcome of the T cell–antigen-presenting cell
(APC) interaction (17). In particular, the off-rate of the
TCR–pMHC complex appears to play a central role (17,
18). The coreceptors CD4 or CD8 can also increase the
avidity of the interaction and/or affect the signaling effi-
ciency via associated proteins such as p56
 
lck
 
 (19–23). Using
binding assays with living CTLs (24) and soluble molecules
in surface plasmon resonance experiments (25), CD8 has
been demonstrated to increase the affinity of the TCR for
cognate pMHC ligand. In contrast to affinity based models,
for effective signaling the need for a conformational change
in the TCR post-ligand binding without a major role for
avidity has also been proposed (26, 27). Furthermore, data
have been presented in support of a requirement for or-
dered oligomerization or aggregation of TCRs (28–30),
which for optimal signaling may be followed by coreceptor
recruitment (31–33). Conformational and affinity/avidity
models are therefore not mutually exclusive; both may be
relevant in “sequential engagement” models (31, 32, 34)
where there is a need for a threshold time of TCR occu-
pancy to be reached to induce the necessary configuration
of TCR–pMHC complexes of a sufficient half-life to allow
coreceptor association. This concept is supported by recent
data demonstrating that CD4 can enhance responses to ag-
onist ligands but not to antagonist ligands due to the
shorter half-life of the TCR antagonist–MHC complex
(31). This is also consistent with the proposed role of ki-
netic proofreading (35, 36) in increasing the fidelity of T
cell recognition.
Toward the aim of better understanding the molecular
nature of T cell recognition, in the current study we have
analyzed the effect of alteration of amino acids in the fourth
hypervariable loop of the TCR 
 
a
 
 chain (HV4
 
a
 
) on T cell
responsiveness. The crystal structure of a TCR V
 
a
 
 domain
indicated that residues in HV4
 
a
 
 are almost coplanar with
the CDR loops, which led to the suggestion that they have
the potential to interact with the pMHC complex (4).
More recently, the structure of a human TCR complexed
with an HIV Tax peptide bound to HLA-A2 (11) shows
that the highly conserved residue K68 of HV4
 
a
 
 contacts
HLA-A2 by forming hydrogen bonds to residues T163 and
E166 of this MHC class I molecule. These amino acids
are conserved in MHC class I but not in class II molecules
(37). However, in other structural studies describing class
I–restricted TCRs, HV4
 
a
 
 residues do not contact pMHC
ligand (10, 12, 13). The functional role of HV4
 
a
 
 residues
in antigen responsiveness has not to date been elucidated,
although recent in vitro binding studies with the soluble
2C (murine) TCR and pMHC have indicated a minor but
significant role for HV4
 
a
 
 residues in contributing to the
binding energy of this interaction (38).
In this study, we have analyzed the role of HV4
 
a
 
 resi-
dues of a TCR derived from the encephalitogenic T cell
hybridoma 1934.4 (39) in antigen responsiveness. Using
the X-ray crystallographic structure of the 1934.4 TCR V
 
a
 
domain as a guide (4), amino acid substitutions of the two
central, exposed residues of HV4
 
a
 
 (Lysine 68 [K68],
glutamic acid 69 [E69]) have been introduced. Wild-type
(WT) and mutated TCRs have been expressed in T cell
transfectants and IL-2 production following antigen expo-
sure analyzed in the presence and absence of CD4 coex-
pression. Our results indicate that in the absence of CD4
coexpression, mutation of K68 to alanine (K68A) results in
greatly reduced IL-2 production, whereas mutation of E69
to alanine (E69A) has a comparatively minor effect. Fur-
thermore, expression of the coreceptor CD4 can compen-
sate for the reduced responsiveness of transfectants bearing
the K68A mutant TCR. The data indicate that HV4
 
a
 
 resi-
dues play an important role in modulating T cell respon-
siveness and support models for T cell activation in which
both affinity of TCR for pMHC ligand and coreceptor
density determine the outcome of the T cell–APC interac-
tion (31, 32, 34).
 
Materials and Methods
 
Cell Lines, Antibodies, and Peptides.
 
The CD4
 
2
 
, TCR 
 
a
 
2
 
b
 
2
 
cell line 58
 
a
 
2
 
b
 
2
 
 (40) was provided by Dr. Stephen Hedrick
(University of California at San Diego, CA), with permission
from Dr. Bernard Malissen (INSERM-CNRS, Marseille-Luminy,
France). The I-A
 
u
 
 expressing B cell line, PL-8 (derived by fusing
LPS-activated splenocytes from H-2
 
u
 
 mice with the M-12.C3
lymphoblast line, [41]) was used as the APC line and was provided
by Dr. David Wraith (University of Bristol, UK). The hybridoma
producing the anti-V
 
b
 
8 mAb F23.1 (42) was a gift from Drs.
John Kappler and Philippa Marrack (University of Colorado
Health Science Center, Denver, CO). Hybridomas expressing
the anti–I-A mAbs Y3P (HB-183), 10.2.16 (TIB-93), and the
anti-CD4 mAb GK1.5 (TIB-207) were obtained from the Amer-
ican Type Culture Collection (ATCC, Rockville, MD). Anti-
CD3
 
e
 
 mAb 145-2C11 (CRL-1975; ATCC) was purchased from
PharMingen (San Diego, CA). The horseradish peroxidase-
conjugated anti–mouse/rat IgG antibodies used as secondary
antibodies for immunofluorescence studies were purchased
from ICN Biomedicals, Inc. (Costa Mesa, CA). The NH
 
2
 
-termi-
nal peptide Ac1-11 of rat myelin basic protein (MBP) and an
analog in which lysine at position 4 is substituted by tyrosine
(Ac1-11[4Y]), were synthesized at the peptide synthesis unit of
the Howard Hughes Medical Institute, UT Southwestern Medi-
cal Center, Dallas, Texas.
 
Expression Plasmids.
 
The 
 
a
 
 and 
 
b
 
 shuttle vectors (43) used as
TCR expression vectors in this study were a kind gift of Dr.
Mark Davis (Stanford University, Palo Alto, CA). The construc-
tion of the 1934.4 
 
a
 
 and 
 
b
 
 chain expression plasmids using the
1934.4 V
 
a
 
 and V
 
b
 
 domain genes (isolated as in reference 44),
was carried out using 1934.4 TCR-specific oligonucleotide
primers and essentially the strategy of Patten and colleagues (43).
Mutagenesis of HV4
 
a
 
 residues K68 and E69 (numbering as in
reference 37; in reference 4 these residues are numbers 67 and 68,
respectively) together with E69 were carried out as described by
Kunkel et al. (45). E69 was substituted by alanine, and K68 and
E69 were both substituted by alanine to generate the mutants 
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E69A and K68AE69A, respectively. The oligonucleotides used
for mutagenesis were: 5
 
9
 
 AGG TGG CTG CTT TAT TG 3
 
9
 
 for
E69A, and 5
 
9
 
 GAG GTG GCT GCT GCA TTG TAT GT 3
 
9
 
for K68AE69A. Mutated bases are indicated by underlining. K68
was substituted by alanine to generate K68A using the splicing by
overlap extension method (46) and the following complementary
oligonucleotides (mutated bases underlined): 5
 
9
 
 GTG GCT TCT
GCA TTG TAT GT 3
 
9
 
 and 5
 
9
 
 ACA TAC AAT GCA GAA
GCC ACC 3
 
9
 
. The presence of the mutations, and the absence
of second site mutations, was confirmed by nucleotide sequenc-
ing using the Thermo Sequenase 
 
33
 
P radiolabeled terminator cy-
cle sequencing system (Amersham, Arlington Heights, IL). All
(sub)cloning steps and PCRs were carried out using standard
methods. An expression plasmid encoding murine CD4 (14) was
a generous gift of Dr. Syamal Datta (Northwestern University
Medical School, Chicago, IL).
 
Generation of Transfectants.
 
For transfections, the 1934.4 
 
a
 
(mutant and WT), 1934.4 
 
b
 
, and CD4 expression plasmids were
purified using Qiagen (Chatsworth, CA) plasmid midi-prep kits.
5 
 
m
 
g of 
 
a
 
 shuttle vector and 10 
 
m
 
g of 
 
b
 
 shuttle vector were used
per transfection. The plasmid encoding the murine CD4 mole-
cule (14) was used together with 
 
a
 
 and 
 
b
 
 shuttle vectors at 10 
 
m
 
g
per transfection. As transfection recipient, the TCR
 
2
 
, CD4
 
2
 
 cell
line 58
 
a
 
2
 
b
 
2
 
 (40) was used (1 
 
3
 
 10
 
7
 
 cells per transfection). Cells
were washed once with ice-cold Hepes-buffered saline, resus-
pended in 0.5 ml phosphate-buffered saline (PBS) and placed on
ice in Bio-Rad (Hercules, CA) electroporation cuvettes (0.4 cm
gap). The relevant constructs were added and mixed with the
cells by gentle pipetting. Cells were kept on ice for 10 min and
pulsed in a Bio-Rad Gene Pulsar at 250V/cm and 960-
 
m
 
F capac-
itance. After pulsing, cells were immediately diluted into ice-cold
non-selective medium (RPMI 1640 supplemented with 10%
FCS, 5 
 
3
 
 10
 
2
 
5
 
 M 2-ME, 100 U/ml of penicillin G, and 100 
 
m
 
g/ml
streptomycin) and placed on ice for 10–15 min. Electroporated
cells were plated into two 96-well plates at 100 
 
m
 
l/well. 2 d later,
100 
 
m
 
l of 2
 
3
 
 selection medium (2 
 
m
 
g/ml mycophenolic acid,
400 
 
m
 
g/ml xanthine) was added per well. 4 d later, 80% of the
medium was replaced with fresh selective medium. Mycophe-
nolic acid–resistant transfectants (30–50 per transfection) were
obtained and screened for surface expression of the transfected
TCRs by flow cytometry.
 
Analysis of Cell Surface Expression of TCR and CD4 by Flow Cy-
tometry.
 
For analysis of cell surface expression of TCR and
CD4, transfectants (1 
 
3
 
 10
 
5
 
/well in a 200 
 
m
 
l volume) were incu-
bated with 10 
 
m
 
g/ml of anti-V
 
b
 
8 mAb (F23.1) or with 10 
 
m
 
g/ml
anti-CD4 mAb (GK1.5) at 4
 
8
 
C for 1 h. Cells were washed three
times with PBS containing 1% BSA (Sigma Chemical Co., St.
Louis, MO) and were incubated with anti–mouse IgG–FITC
conjugate for TCR staining or anti–rat IgG–FITC conjugate for
CD4 staining at 4
 
8
 
C for 1 h. Controls were incubated with sec-
ondary conjugates only. Cells were washed three times with 1%
BSA containing PBS, resuspended in PBS, and analyzed in a flow
cytometer (Becton Dickinson). Results were analyzed using the
Cellquest program.
 
Stimulation by Cross-Linking Antibodies or PMA/Ionomycin.
 
Transfectants (1 
 
3
 
 10
 
5
 
/well in 96-well plates) were stimulated ei-
ther with 10 ng/ml PMA 
 
1
 
 500 ng/ml ionomycin, plate-bound
anti-V
 
b
 
8 antibody, F23.1, or plate bound anti-CD3
 
e
 
 antibody,
145-2C11. For the antibody stimulations, plates were incubated
overnight with 10 
 
m
 
g/ml antibody and washed twice with PBS
before adding the transfectants. Controls were run in parallel
without any stimulation. Culture supernatants were harvested af-
ter 24 h, and after a single freeze-thaw, 80 
 
m
 
l aliquots were incu-
bated with an IL-2–dependent cell line, CTLL-2 (TIB214;
ATCC; 5 
 
3
 
 10
 
3
 
 cells/well). Cells were pulsed 24 h later with
1 
 
m
 
Ci of 
 
3H/well for 16–18 h and thymidine incorporation
analyzed by liquid scintillation spectroscopy (LKB Pharmacia,
Uppsala, Sweden). All assays were done in triplicates and data is
expressed as mean values of triplicate measurements following
background subtraction (in cpm) 6 SD.
Stimulation by Cognate Peptide:MHC Class II. Transfectants (1 3
105/well in 96-well plates) were incubated with graded doses of
the peptides Ac1-11 or Ac1-11[4Y] together with PL-8 cells (1 3
105/well) as APCs. No peptide was added to the control wells. For
anti-CD4 or anti–I-Au inhibition, graded doses of anti-CD4
(GK1.5) or anti–I-A (Y3P, 10.2.16) mAbs were used. Appropriate
isotype matched antibodies were used as controls. The responses of
transfectants were measured by IL-2 production that was detected
by the proliferative response of CTLL-2 cells as above. All stimula-
tion assays were done in triplicates and data expressed as percent of
response to the plate-bound anti-CD3e antibody, 145-2C11.
Circular Dichroism (CD) Analyses. Far-ultraviolet CD analy-
ses were performed as previously described (44), using an AVIV
model 60DS circular dichroism spectrophotometer at 258C and a
cell of 0.2 cm path length.
Results
Generation of WT and Mutant TCR Transfectants. To
analyze the effects of mutating HV4a residues 68 and 69 of
the 1934.4 TCR on antigen responsiveness, WT and mu-
tated  a chain genes were transfected with the WT b
(Vb8.2-Jb2.3) chain into a TCRa2b2 thymoma, 58a2b2
(40). This murine T cell thymoma line lacks an endoge-
nous TCR, but has a functional CD3–TCRz complex that
can be expressed on the cell surface with the transfected
TCR a and b chains. Fig. 1 shows the location of the resi-
dues that were targeted for mutagenesis on the X-ray crys-
tallographic structure of the 1934.4 Va domain (4).
Mycophenolic acid–resistant transfectants were analyzed
for expression levels of surface TCR by flow cytometry us-
ing a Vb8-specific mAb, F23.1. Since the expression levels
varied between transfectants, transfectants with comparable
Figure 1. a-carbon trace of the structurally solved 1934.4 Va domain
(grey) associated with the modeled 1934.4 Vb domain (black) (4). HV4a
residues K68 and E69 are shown with their side chains in black. The fig-
ure was generated using the programs Bobscript and Raster3D (70, 71).512 Role of a Chain Fourth Hypervariable Loop in T Cell Recognition
levels of surface TCR were chosen for further analysis (Fig.
2). These transfectants were analyzed for responsiveness (as-
sessed by quantitating IL-2 production) to PMA in addition
to anti-Vb8 (F23.1) and anti-CD3e (145-2C11) antibody-
mediated cross-linking. Responses to all three types of
stimulation did not differ markedly, indicating that the sig-
naling machinery of the transfectants was intact and that the
Va mutations do not affect signaling via antibody-mediated
b chain cross-linking (Fig. 2 D). Differences observed upon
145-2C11 (Fig. 2 C) stimulation probably reflect minor
differences in the surface TCR levels observed in Fig. 2 A.
To control for variability, responses to cognate pMHC (be-
low) have been normalized with respect to those obtained
from stimulation with 145-2C11 and expressed as percent-
ages of 145-2C11 responses. A similar approach was taken
by Patten and colleagues for the analysis of anti-cytochrome
c–I-Ek responses by transfectants expressing the WT 2B4
TCR and its mutated derivatives (43).
Responsiveness of WT and Mutant Transfectants to Cognate
Antigen. The 1934.4 TCR recognizes the NH2-terminal
11-mer (or nonamer) of myelin basic protein (MBP) asso-
ciated with I-Au and the acetylation of the NH2 terminus
of this peptide (abbreviated to Ac1-11) is essential for T cell
recognition (39). Position 4 analogs (position 4 substituted
by alanine and tyrosine, designated Ac1-11(4A) and Ac1-
11(4Y), respectively) of this peptide bind with higher affin-
ity to I-Au (47, 48), resulting in shifts of dose response
curves of 1934.4 hybridoma cells (47). We tested the ability
of the WT versus mutant transfectants to recognize the
Ac1-11 peptide presented in the context of the MHC class
II molecule I-Au. When Ac1-11 was used for stimulation
(Fig. 3 A), the WT transfectants respond, albeit poorly,
whereas there is an almost undetectable response observed
for the three types of mutant transfectants (K68A, E69A,
and K68AE69A). This poor responsiveness is most likely
due to the lack of CD4 expression by the transfectants,
which in other systems is known to decrease antigen re-
sponsiveness (31, 49). Therefore, to make quantitative
comparisons between the WT and mutant transfectants in
the absence of CD4, we tested their responses to the higher
affinity peptide Ac1-11(4Y). Fig. 3 B shows that the re-
sponse of the WT transfectants to Ac1-11(4Y) is signifi-
cantly better compared with their response to Ac1-11 (Fig.
3 A), and this is reminiscent of the data of others for the
parent 1934.4 hybridoma (47, 48, 50). The mutant trans-
fectants also show higher and detectable levels of responses
to the higher affinity peptide. Replacement of glutamic
acid at position 69 with alanine (E69A) results in a slight,
but significant, reduction in response as compared with
WT; however, the double mutants (K68AE69A) and the
Figure 2. Surface expression of TCR on WT and mutant transfectants and responsiveness
to antibody-mediated cross-linking or PMA stimulation. (A) Cells were stained with the
anti-Vb8 mAb F23.1 (10 mg/ml), followed by anti–mouse Ig-FITC. Controls (shaded
curves) were incubated with the secondary antibody only. For analyses of responsiveness,
transfectants (1 3 105) were stimulated with (B) 10 ng/ml PMA 1 500 ng/ml ionomycin, or
(C) 10 mg/ml plate-bound anti-CD3e mAb 145-2C11, or (D) anti-Vb8 mAb F23.1. IL-2
production was quantitated using the IL-2–dependent cell line, CTLL-2. Background cpm
were ,4000 cpm for all transfectants. The stimulation data are representative of three inde-
pendent experiments.513 Thatte et al.
K68A mutants show substantial decreases in their responses
relative to WT transfectants.
The data indicate that lysine at position 68 of HV4a
plays a crucial role in the TCR–pMHC interaction, most
likely by either directly contacting Ac1-11–I-Au or indi-
rectly by affecting the conformation of neighboring CDRs
in the Va domain. Importantly, several observations indi-
cate that the mutations analyzed in this study do not have
significant effects on the conformation of the TCR Va
domain. First, the WT and mutant transfectants express
similar levels of surface TCR, and aberrant folding of the
TCR a chain due to mutation would be expected to affect
this. Second, CD spectroscopic analysis of the WT and mu-
tant Va domains, expressed as recombinant proteins in Esch-
erichia coli, indicate that the Va domains are folded into
structures of high b-sheet content (data not shown). Unfor-
tunately, the lack of an anti-Va4.2 antibody that is conforma-
tionally dependent precludes analyses using such a reagent.
CD4 Coexpression Enhances the Responsiveness of the Trans-
fectants. Since the differences in response to peptide were
most striking between the WT and the K68A mutant,
transfectants expressing these TCRs were analyzed further.
The T cell coreceptor, CD4, has been shown to enhance
the capability of thymocytes and mature T cells to recog-
nize antigen (reviewed in references 19 and 51). To analyze
whether CD4 can compensate for the effect of the K68A
mutation, cotransfections of the 1934.4 WT or K68A mu-
tant a chain together with WT b chain and CD4 expres-
sion constructs using the 58a2b2 thymoma cell line as re-
cipient were carried out. The surface TCR and CD4 levels
are comparable between the WT and K68A transfectants
(Fig. 4 A), although the TCR levels for the transfectant
K68A/CD4-32 are slightly lower. These CD41 transfec-
tants show similar responses to 145-2C11 and F23.1 stimu-
lation (Fig. 4, B and C). In addition to shifting the dose re-
sponse curve of the WT transfectants, cotransfection of
CD4 almost completely (K68A/CD4-12 mutant) or par-
tially (K68A/CD4-32 mutant) restores the K68A mutant
responses to cognate pMHC to the levels seen with the
WT transfectant, WT/CD4-43 (Fig. 5). The WT transfec-
tant WT/CD4-33 is, however, still more responsive than
the two mutant transfectants and this is particularly so for
the Ac1-11 peptide (Fig. 5 A). This significant gain of
function for the K68A mutants suggests that either the in-
creased avidity and/or enhancing the efficiency of TCR
signaling by CD4 coexpression can compensate, in part at
least, for the suboptimal nature of the K68A TCR–pMHC
interaction. In addition, the enhancing effect of CD4 is
much greater for the K68A mutants than for the WT trans-
fectants (Figs. 3 and 5).
To demonstrate that the increased IL-2 production by
the K68A mutants is due to CD4 coexpression, the sensi-
tivity of the WT and K68A transfectant responses follow-
ing Ac1-11(4Y)–I-Au exposure to blockade by the anti-
Figure 3. Responses of transfectants to MBP peptides. 105 PL-8 cells/well were cocultured with 105 transfectants/well and the concentrations of (A)
Ac1-11, or (B) Ac1-11[4Y] peptides as shown. Culture supernatants were harvested at 24 h and analyzed for IL-2 activity as in Fig. 2. Data is expressed
as percent of 145-2C11 response shown in Fig. 2. SDs were ,15%. Background cpm were ,4000 cpm for all transfectants. The data shown are from
one representative experiment of a total of three separate experiments.514 Role of a Chain Fourth Hypervariable Loop in T Cell Recognition
CD4 mAb GK1.5 was investigated. K68A transfectants are
significantly more sensitive to the effects of GK1.5 than the
WT transfectants (Fig. 6 A). Importantly, this difference is
observed for K68A/CD4-12 relative to WT/CD4-43, and
these two transfectants show essentially the same dose re-
sponse to Ac1-11(4Y)–I-Au. The effects of GK1.5 are con-
sistent with the observation that WT transfectants without
CD4 coexpression are responsive to antigen, in contrast to
the K68A transfectants (Fig. 3). Finally, the sensitivity of
the WT and K68A transfectants to blockade by anti–I-A
antibodies was also investigated, because this was expected
to reveal differences in affinities of the corresponding
TCR–pMHC complexes. Two anti–class II mAbs (10-
2.16 and Y3P) that recognize I-Au were used, and for both
anti–MHC class II antibodies the K68A transfectants are
more sensitive to inhibition than the WT transfectants (Fig.
6 B; data shown only for 10.2.16). As with the GK1.5 inhi-
bition, this difference in sensitivity to anti–MHC class II
inhibition is seen when the WT/CD4-43 and K68A/
CD4-12 transfectants are compared. Taken together with
the similarity of the dose responses to cognate antigen in
the absence of antibodies for these two transfectants (Figs. 5
and 6), this indicates that the affinity of the K68A TCR for
cognate antigen is lower than that of the WT TCR.
Discussion
To date, there are no high-resolution structural data
available for a TCR–pMHC class II complex, but func-
tional studies (14, 15) of class II–restricted TCRs indicate
that the orientation of the TCR is similar to the diagonal
configuration observed in the X-ray structures of several
class I–restricted TCRs (10–13). The crystal stuctures indi-
cate that HV4a residues sometimes (11), but not always
Figure 4. Cell surface expression of TCR and CD4 by transfectants and responsiveness to
antibody-mediated cross-linking. (A) Surface TCR expression (left-hand histograms) was
analyzed by staining cells with the anti-Vb8 mAb F23.1 (10 mg/ml; thick lines), followed by
anti–mouse Ig-FITC. Controls (shaded) were incubated with the secondary antibody only.
For CD4 staining (right-hand histograms) the anti-CD4 mAb, GK1.5 (10 mg/ml; thick
lines), followed by anti–rat Ig-FITC antibody were used. Controls (shaded) were treated
similarly as for TCR staining. Data from 104 cells was collected on FACScan® flow cytome-
ter (Becton-Dickinson) and analyzed using the Cellquest program. For antibody-mediated
cross-linking, transfectants (5 3 104) were stimulated with (B) plate bound anti-CD3e mAb
145-2C11, or (C) plate bound anti-Vb8 mAb F23.1. To coat wells of 96-well plates, anti-
bodies were used at 10 mg/ml. IL-2 activity in the culture supernatants was analyzed using
the IL-2–dependent cell line, CTLL-2. Background cpm were ,3000 cpm for all transfec-
tants. The stimulation data are representative of three separate experiments. All transfectants
gave similar but lower responses with antibodies coated at 3 and 5 mg/ml, indicating over-
lapping dose response curves (data not shown).515 Thatte et al.
(10, 12, 13), make contact with cognate ligand. In addition,
binding studies using a recombinant class I–restricted TCR
indicate a minor contribution for these residues to the
binding energy of the interaction (38). However, the func-
tional relevance of HV4a residues in T cell activation have
not, to our knowledge, been investigated for either class I–
or class II–restricted TCRs, and the current study addresses
this issue for an autoreactive TCR that recognizes MBP
Ac1-11 bound to I-Au. In contrast to amino acids located in
HV4a, the functional significance of HV4b residues have
been more extensively analyzed, and this TCR region is
known to play a role in contacting several bacterial and en-
dogenous superantigens (52–54). In addition, recent model-
ing/X-ray structural studies for the interaction of the mu-
rine 2C TCR with allo-ligand have indicated that the
HV4b residue R69 might contribute toward the binding
energy through electrostatic effects (55).
Our findings identify a role for HV4a residues of the
1934.4 TCR in pMHC recognition. This is consistent
with the X-ray crystallographic structure of the 1934.4 Va
domain (Va4.2), in which HV4a forms part of a relatively
flat continuous surface with CDR1, 2, and 3, leading to the
Figure 5. Responses of transfec-
tants to Ac1-11 and the higher affin-
ity analog Ac1-11[4Y]. 5 3 104
PL-8 APCs/well were cocultured
with 5 3 104 transfectants/well and
the concentrations of (A) Ac1-11, or
(B) Ac1-11[4Y] peptides as shown.
Culture supernatants were harvested
after 24 h and analyzed for IL-2 ac-
tivity as in Fig. 2. Data is expressed
as percent of 145-2C11 response
shown in Fig. 4. Background cpm
were ,3000 cpm for all transfec-
tants. SDs were ,12%, and the data
are representative of three indepen-
dent experiments. Simultaneous
analysis of CD41 and CD42 trans-
fectants led to similar results to those
shown in Figs. 3 and 5 (data not
shown).
Figure 6. Effect of anti-CD4 and
anti–MHC class II antibodies on the
responses of the transfectants to pep-
tide. Transfectants (5 3 104/well)
were cocultured with PL-8 APCs
(5 3 104/well) and 0.3 mg/ml of
Ac1-11[4Y] peptide in the absence
or presence of the concentrations of
(A) the anti-CD4 antibody, GK1.5,
or (B) the anti–MHC class II anti-
body, 10-2.16, as shown. Superna-
tants were harvested after 24 h and
analyzed for IL-2 as in Fig. 2. Ap-
propriate isotype matched control
antibodies (rat IgG2b for GK1.5,
and mouse IgG2b for 10-2.16) were
used at 10 mg/ml. Background cpm
were  ,1500 cpm for all transfec-
tants. Data are representative of two
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earlier suggestion that it might be involved in interactions
with cognate pMHC ligand (4). In the current study, the
role of the two central exposed residues (K68, E69) of this
loop in pMHC recognition have been investigated by ex-
pressing 1934.4-derived TCRs with mutations to alanine at
these positions in T cell transfectants. K68 is highly con-
served in murine and human Va sequences, whereas the
variability at position 69 is higher (37). Antigen responsive-
ness of the TCR transfectants has been analyzed in the
presence and absence of CD4 coexpression and compared
with that of 1934.4 WT transfectants. These studies have
shown that K68 plays an important role in antigen respon-
siveness, as assessed by quantitating IL-2 secretion, whereas
E69 has a lesser role. In addition, mutation of both K68
and E69 to alanine within the same TCR results in respon-
siveness to Ac1-11(4Y)–I-Au complexes that is intermedi-
ate between that of the transfectants expressing K68A and
E69A TCRs. However, transfectants expressing this double
mutant show an almost undetectable response similar to
that of the K68A mutants when presented with the lower
affinity peptide Ac1-11 in the context of I-Au. Thus, the
effect of the double mutation appears to be analogous to
that of the K68A mutation, reiterating the importance of
K68 in the interaction.
The role of K68 in pMHC responsiveness of the 1934.4
TCR could be through several possible mechanisms that
are not mutually exclusive. First, K68 may contact either
peptide or I-Au (or both) in the pMHC complex either di-
rectly or via ordered water, which has been shown to play
a role in stabilizing antibody–antigen interactions (56, 57).
Electrostatic interactions, which can occur over distances
up to 20 Å (58), may also occur between K68 and cognate
pMHC. Consistent with this possibility and assuming that
the I-Au structure is similar to that of the recent I-Ak/I-Ad
structures (59, 60), several acidic I-Abu residues (E84, E85;
numbering as in reference 37) would contact/be in prox-
imity to HV4a if the orientation of 1934.4 TCR binding
resembles that in TCR–pMHC class I complexes (10–13).
Alternatively, the effects of mutation of K68 may be indi-
rect through destabilization of other CDR loops of Va4.2
that are involved in pMHC binding. However, we favor a
more direct effect of the mutation, since the X-ray crystal-
lographic structure of Va4.2 (4) indicates that K68 is ex-
posed and does not make stabilizing H-bonds with CDR
residues. Furthermore, it is unlikely that the mutations ana-
lyzed in this study have resulted in gross structural pertur-
bations since the CD spectra of the corresponding recom-
binant Va domains indicate that they are correctly folded,
and the WT and mutant transfectants express similar levels
of surface TCR.
Regardless of the mechanism by which the effect of mu-
tation of K68 occurs, the almost total abrogation of respon-
siveness of the CD42 mutant transfectants to Ac1-11–I-Au
complexes is unexpected since K68 would be predicted to
be at the periphery of the interacting surfaces of TCR and
pMHC. However, the absence of CD4 together with the
low affinity of this peptide for I-Au most likely contribute
toward the unresponsiveness, and in this context CD42
WT transfectants also respond relatively poorly to this
ligand. In contrast, when the density of cognate pMHC is
increased by using Ac1-11(4Y) which has a z1000-fold
higher affinity for I-Au (61), responsiveness of the K68A
and K68AE69A transfectants is observed albeit at consider-
ably lower levels than that of the WT transfectants. This
supports the concept that the K68A mutant TCR binds to
cognate antigen (Ac1-11–I-Au complexes) with an affinity/
avidity which, in the absence of CD4, falls below the
threshold needed for effective signaling (IL-2 production in
the current study). Consistent with this, coexpression of CD4
partially compensates for the defective signaling of transfec-
tants expressing K68A. The enhancing effect of CD4 could
be through one or more mechanisms. First, CD4 may in-
crease the affinity/avidity of the TCR for pMHC by stabi-
lizing the trimeric complex via CD4–MHC interactions
(19–21, 33), or by increasing the affinity of the TCR-
pMHC interaction in an analogous way to that demon-
strated for CD8 (24, 25). Second, CD4 is able to recruit the
phosphotyrosine kinase p56lck to the TCR–CD3 complex
increasing the strength of the signal delivered postantigen
recognition by the TCR (22, 23). In the current study,
this could compensate for the loss in affinity of the K68A
mutant. Consistent with this, several studies have shown a
significant loss of CD4 effects on T cell activation in the
absence of p56lck-CD4 interaction (62–64). However,
CD4 lacking its cytoplasmic lck-binding domain can still
augment T cell reactivity (65), and in one study the extra-
cellular domains of CD4 and not its cytoplasmic tail are re-
sponsible for restoration of IL-2 secretion (66).
Recent studies have shown that reduced CD4 availabil-
ity can convert the functional and biochemical effects of
agonist peptides into those characteristic of partial agonists
(32) or partial agonists into antagonists (67, 68). Recipro-
cally, CD4 coexpression can convert partial agonists into
agonists, but has no effect on antagonist activity (31). The
lack of effect of CD4 on antagonists which form short-
lived TCR–pMHC complexes (17) supports the hypothesis
that CD4 engagement follows TCR–pMHC complex for-
mation, and that the latter complex needs to be sufficiently
long lived to allow CD4 recruitment (31, 32). By exten-
sion, in the current study, the enhancing effect of CD4
coexpression on the responsiveness of the K68A mutant
suggests that the half life of the K68A TCR–pMHC in-
teraction is long enough to allow CD4 recruitment to the
ternary TCR–pMHC complex. However, without CD4
coexpression, the interaction of this TCR with Ac1-11–I-Au
complexes appears to be below the threshold needed for T
cell activation. In contrast, the WT 1934.4 TCR–pMHC
interaction appears to be sufficiently long lived in the ab-
sence of CD4 to result in signaling. This is also consistent
with the relative resistance of this latter interaction to
blockade by the anti-CD4 antibody, GK1.5. In addition,
the enhancement in responsiveness by CD4 coexpression is
much greater for the K68A mutant than the WT TCR.
The effect of CD4 therefore appears to be maximal for
suboptimal TCR–pMHC interactions that attain a thresh-
old affinity, and this is consistent with observations using517 Thatte et al.
other antigen recognition systems (31, 69). However, in
these other systems, the effects of CD4 on responses to ag-
onists/partial agonists/antagonists were analyzed, and this is
in contrast to the current study where the affinity of the
TCR–pMHC (agonist) interaction has been affected by
mutating the TCR. Taken together, our data provide fur-
ther support for sequential engagement models of T cell
signaling in which both the affinity (off-rate) of the TCR–
pMHC complex and coreceptor involvement affect the
outcome of T cell contact with APCs bearing cognate
ligands (31, 32, 34).
In summary, a single amino acid substitution of the ex-
posed, highly conserved residue K68, which is located out-
side the CDRs of the TCR, appears to have a significant
impact on the outcome of the interaction between a TCR
and its pMHC ligand. Given the indications that the diago-
nal orientation observed for the binding of class I–restricted
TCRs to pMHC complexes is general (10–13), it is likely
that the functional role of this HV4a amino acid that we
have defined will be observed for other TCR–pMHC in-
teractions.
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